Is Nystatin (antifungal) effective for treating vaginal yeast infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nystatin for Vaginal Yeast Infections

Nystatin is effective for treating vaginal yeast infections but is inferior to topical azole antifungals (clotrimazole, miconazole) and should be reserved as a second-line option, particularly for azole-resistant cases or recurrent infections caused by non-albicans Candida species. 1, 2

Why Azoles Are Preferred Over Nystatin

  • Topically applied azole drugs are more effective than nystatin for vaginal candidiasis, achieving symptom relief and negative cultures in 80-90% of patients who complete therapy. 1

  • The CDC explicitly states that azoles outperform nystatin in treatment efficacy, which is why nystatin requires a longer 14-day treatment course compared to 1-7 days for most azole regimens. 1

  • Comparative studies confirm that while nystatin achieves cure rates of approximately 78%, it has significantly higher relapse rates compared to azole antifungals like miconazole and clotrimazole. 3

When Nystatin May Be Appropriate

  • Nystatin demonstrates particular effectiveness for recurrent vulvovaginal candidiasis (RVVC) caused by C. glabrata (64.3% cure rate) or fluconazole-resistant Candida species, where it may outperform oral fluconazole. 4

  • For patients who have failed azole therapy or have documented azole-resistant infections, nystatin 100,000-unit vaginal tablets for 14 days represents a viable alternative. 1, 4

Critical Prescribing Details

Important caveat: The FDA-labeled nystatin cream formulation is NOT indicated for intravaginal use—only the vaginal tablet formulation (100,000 units) should be used for vaginal candidiasis. 5

  • The standard nystatin regimen is one 100,000-unit vaginal tablet daily for 14 days, which is considerably longer than the 1-7 day courses typical of azole therapy. 1

  • Oil-based vaginal preparations may weaken latex condoms and diaphragms, requiring counseling about barrier contraception during treatment. 1

Recommended Treatment Algorithm

For uncomplicated vaginal candidiasis (first-line):

  • Use topical azoles: clotrimazole 1% cream for 7-14 days OR miconazole 2% cream for 7 days OR single-dose oral fluconazole 150 mg. 1, 2

For recurrent or azole-resistant cases (second-line):

  • Consider nystatin 100,000-unit vaginal tablets for 14 days, particularly if C. glabrata or fluconazole resistance is suspected. 1, 4

For severe or complicated cases:

  • Multi-day azole regimens (7-14 days) remain preferred over nystatin due to superior efficacy and lower relapse rates. 2, 3

Follow-Up Considerations

  • Patients should return only if symptoms persist after completing treatment or recur within 2 months of initial symptoms. 1, 2

  • Treatment of sexual partners is not routinely recommended for vulvovaginal candidiasis but may be considered in women with recurrent infections. 1

  • Premature discontinuation of nystatin's 14-day course can lead to treatment failure, so emphasize completing the full regimen even if symptoms improve early. 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Yeast Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Breast Yeast Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.